TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation
暂无分享,去创建一个
Wataru Okamoto | Masahiro Fukuoka | Kazuhiko Nakagawa | P. Jänne | M. Fukuoka | Kaoru Tanaka | K. Nishio | I. Okamoto | H. Yamaguchi | K. Kuwata | K. Nakagawa | T. Arao | Tokuzo Arao | Kazuto Nishio | Isamu Okamoto | Pasi A. Jänne | E. Hatashita | Kaoru Tanaka | Kiyoko Kuwata | Haruka Yamaguchi | Erina Hatashita | Yuki Yamada | W. Okamoto | Y. Yamada
[1] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[2] K. Sugio,et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. , 2010, Lung cancer.
[3] B. Zbar,et al. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. , 2002, The Journal of clinical investigation.
[4] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[5] N. J. McNally,et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). , 1998, British Journal of Cancer.
[6] P. Workman,et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. , 1988, British Journal of Cancer.
[7] K. Tashiro,et al. Molecular cloning and expression of human hepatocyte growth factor , 1989, Nature.
[8] G. Watanabe,et al. Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2009, Clinical Cancer Research.
[9] M. Fukuoka,et al. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. , 2007, Cancer research.
[10] H. Moses,et al. Stromal fibroblasts in cancer initiation and progression , 2004, Nature.
[11] Y. Yatabe,et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.
[12] D. Yee,et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. , 2008, The Journal of clinical investigation.
[13] W. Birchmeier,et al. Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.
[14] William Pao,et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.
[15] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[16] R. Ball,et al. IMMUNOREACTIVITY FOR HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR AND ITS RECEPTOR, met, IN HUMAN LUNG CARCINOMAS AND MALIGNANT MESOTHELIOMAS , 1996, The Journal of pathology.
[17] Kaoru Tanaka,et al. SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion , 2009, International journal of cancer.
[18] Luca Toschi,et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.
[19] A. Marcus,et al. Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. , 2001, Human pathology.
[20] E. Hudson,et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. , 1997, Cancer research.
[21] Toshikazu Nakamura,et al. Hepatocyte growth factor and the Met system as a mediator of tumor–stromal interactions , 2006, International journal of cancer.
[22] D. Brewster,et al. Trends in cancer incidence and mortality in Scotland: description and possible explanations. , 1998, British Journal of Cancer.
[23] T. Nakamura,et al. Hepatocyte growth factor/scatter factor is an autocrine factor for human normal bronchial epithelial and lung carcinoma cells. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[24] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[25] R. Salgia,et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. , 2002, Cytokine & growth factor reviews.
[26] M. Fukuoka,et al. Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition , 2010, Molecular Cancer Therapeutics.
[27] B. Elliott,et al. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. , 1996, The American journal of pathology.
[28] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[29] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[30] J. Rubin,et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.
[31] G. Michalopoulos,et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. , 1991, Oncogene.